LUMBY, British Columbia, Dec. 26 /PRNewswire-FirstCall/ -- avVaa World Health Care Products Inc. , a global biotechnology company offering therapeutic, natural skin and health care products, announced today that Dr. Mark Alden, avVaa VP of Research and Board Member, reports that an on-going eczema/psoriasis study for NEUROSKIN Forte at the University of Medicine and Dentistry of New Jersey (UMDNJ) is expected to be 50% complete by mid-January. A well-qualified dermatology research team at the UMDNJ is conducting this study.
Dr. Alden is also launching a clinical trial with NEUROSKIN Radiation Skin Soother & Moisturizer at the Cancer Treatment Center of America's Eastern Regional Medical Center in Philadelphia. Dr. Alden, as Vice Chair of Radiation Oncology at Drexel University College of Medicine, will be the Principal Investigator on this study, which is expected to begin by the end of December 2006.
"We are excited about all of the recent attention avVaa's NEUROSKIN products are receiving in the research field. Toward that end, we will be exhibiting at the American Academy of Dermatology Annual Meeting in Washington, D.C. this February, attended by thousands of dermatologists, and is the largest dermatology meeting of the year. Concurrently, we will be implementing an associated advertising campaign that to tie in to our attendance at the conference," said avVaa VP of Research and Board Member Dr. Alden.
Alden continued, "The results of a recent German trial comparing NEUROSKIN Forte (Psoriasis) and NEUROSKIN Mild will be published as part of that ad campaign and have already been presented at the New Jersey Technology Council conference on nanotechnology that we attended this past summer."
Along with his Vice Chair of Radiation Oncology position at Drexel University College of Medicine, avVaa VP and Board Member Dr. Alden is also distinguished as a Vice Chairman of Radiation Oncology at the Hahnemann University Hospital in Philadelphia.
Now the principal investigator on a number of avVaa products studies, Dr. Alden has previously served as the Chairman, Radiation Oncology Department at Wilkes-Barre General Hospital in Wilkes-Barre, PA; and Medical Director, TriCounty Regional Cancer Center, in Southampton, PA. In addition, Dr. Alden has submitted a number of grant applications, and held many positions in medical education, working closely with researchers. Dr. Alden has been published in several journals, including the Journal of Chemical Education and Radiology.
In addition to his role at avVaa, Dr. Alden is also currently the Chairman of the Cancer Committee for Cancer Treatment Center of America's Eastern Regional Medical Center.
About avVaa World Health Care Products
avVaa World Health Care Products is a global biotechnology company that specializes in effective, all natural, therapeutic skin care products that improve quality of life and well being for consumers. avVaa's patented European skin care formulas are scientifically registered, FDA- Compliant, and were developed to relieve and treat the symptoms of common skin ailments, including: eczema, psoriasis and acne. avVaa is poised to manufacture and market its OTC NEUROSKIN line of skin care products through mass, food and drug channels in the United States and globally.
The Company's second generation of its unique, high-quality therapeutic skin care products includes a comprehensive line of Animal Care products designed to capture its share of the $44 billion+ worldwide animal care and products market. avVaa sells its quality Animal Care products through partnerships with established distributors and retailers in both Canada and the United States.
For additional information on avVaa, contact Jack Farley CEO / Chairman, at 1-866-772-8822 or visit: www.avvaa.com or www.otcfn.com/avvw.
CONTACT: Investor Relations, Merle Goertz (West Coast) of avVaa World Health Care Products, 1-604-688-2349; or Rick McCaffrey of OTC Financial Network, 1-781-444-6100 ext. 625.
Safe Harbor: Statements contained in this press release that are not based upon current or historical fact are forward looking in nature. Such forward- looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of AVVAA World Health Care Products, Inc. and no assurance can be given that such results will be achieved. Potential risks and uncertainties include but are not limited to the ability to procure, properly price, retain, and successfully complete projects, the availability of technical personnel, changes in technology, and competition.
avVaa World Health Care Products Inc.CONTACT: Jack Farley, CEO - Chairman of avVaa, +1-866-772-8822; orInvestor Relations, Merle Goertz (West Coast) of avVaa World Health CareProducts, +1-604-688-2349; or Rick McCaffrey of OTC Financial Network,+1-781-444-6100, ext. 625
